Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.40 |
| ▸ | MEN1 | O00255 | 8/20 | 0.40 |
| ▸ | USP2 | O75604 | 8/20 | 0.40 |
| ▸ | CASP1 | P29466 | 8/20 | 0.40 |
| ▸ | CASP7 | P55210 | 8/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2405585 | 0.99 | ADRB1 (0.43) | ADRB1FLT3ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2400813 | 0.87 | MET (0.46) | FLT3ALDH1A1CYP1A2CYP3A4MEN1 | |
| SCHEMBL2401935 | 0.82 | ADRB1 (0.45) | ADRB1FLT3ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2401844 | 0.82 | LMNA (0.37) | ALDH1A1CYP1A2CYP3A4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2402650 | 0.81 | ADRB1 (0.44) | ADRB1FLT3ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2405574 | 0.81 | HRH4 (0.46) | ADRB1FLT3ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2402477 | 0.79 | CHEK1 (0.37) | ALDH1A1CYP3A4MEN1KMT2ACYP2C9 | |
| SCHEMBL2402203 | 0.77 | GBA1 (0.49) | ALDH1A1CYP1A2MEN1KMT2ACYP2C9 | |
| SCHEMBL2404750 | 0.77 | FLT3 (0.42) | ADRB1FLT3ALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL2401812 | 0.76 | FLT3 (0.43) | ADRB1FLT3ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545058-B1 | TETRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS INHIBITORS OF HISTAMINE RECEPTORS | KALYPSYS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2545058-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2011112766-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | ADRB1 569/4885FLT3 1548/4885ALDH1A1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.